KPTI — Stock Film
STOCK FILMSCENE 1/11KPTI · $1.82
Stock Expert AI presents
KPTI
Karyopharm Therapeutics Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Karyopharm Therapeutics Inc. A quick introduction.

On the stock market since 2013, it operates in the world of health and science. It has 228 employees. Now — the numbers.

on the stock market since 2013
228 employees
$45.8M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $2.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
98%License and Service
License and Service 98%Health Care, Other 2%
98% of all revenue comes from a single line: License and Service.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $233.6M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
38
weak

Clearly below the class average.

FINANCIAL STRENGTH
53
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
4
very weak

Clearly below the class average.

GROWTH
27
very weak

Clearly below the class average.

PRICE MOMENTUM
8
very weak

Clearly below the class average.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Each sale is made at a loss3/10
Costs eat into the margin4/10
WORTH WATCHING

Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales are holding up

The company sells $146.1M a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 25 buys and 18 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $13.20625% above today’s price.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $196.0M against $146.1M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, KPTI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: KPTI is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (4/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film